Hey, wait up Am­gen and Mi­rati, Boehringer In­gel­heim is join­ing the KRAS crowd as ear­ly suc­cess in­spires ri­vals

It doesn’t take long for hot new can­cer tar­gets to at­tract a bustling field of ri­vals. Take KRAS, for ex­am­ple.

To­day you can add Boehringer In­gel­heim to the group with clin­i­cal-stage KRAS as­sets to boast about. In­ves­ti­ga­tors pre­sent­ed their pre­clin­i­cal case for the oral KRAS in­hibitor BI 1701963 in Boston to­day, and un­veiled plans to go af­ter a full slate of KRAS mu­ta­tions in a move aimed be­yond just G12C, where Am­gen and Mi­rati are now vy­ing for the lead with promis­ing, but very ear­ly, lung can­cer da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.